Psychotropic medication plays a crucial role in the field of mental illness,and the issues of drug efficacy and safety due to individual differences cannot be ignored.Genetic factors,especially the genetic poly-morphisms related to drug-metabolizing enzymes,drug action targets,and risk,have a significant impact on drug responses.Pharmacogenomics,by detecting genetic polymorphisms,can reveal a patient's inherited tend-encies towards drug efficacy,pharmacokinetic characteristics,and potential toxicity,thereby predicting the therapeutic effects and adverse reactions of drug treatment,and providing guidance for personalized therapy.Therefore,individualized medication based on pharmacogenomics helps to improve cure rates,reduce relapse rates,and decrease medical costs,which is of great significance to clinical medication in mental illness.

Objective To observe the effect of over-expressed amyloid procursor protein(APP) gene on the cholinergic receptor binding and the ChAT activity in human neuroblastoma cell line SH-SY5Y.Methods SH-SY5Y cells were transfected with pCMV695 plasmid containing wild type human APP695 gene by Lipofectamine 2000 method.The expression of APP was detected by Western blot.A? contents were test by ELISA assay in over-expression SH-SY5Y cell clones(SH-SY5Y-APP).The special binding of muscarinic and nicotinic cholinergic receptors in those A?-overproducing cell clones was determined by radio-ligand binding method.The cholinergic acetyl transferase(ChAT) activity was assayed by radiao-immunoassay.Results No evident morphologic changes of cytotoxicity were detected after transfection.When A? production was 2～2.6 times as much as that of normal cells,muscarinic receptor binding was decreased from 18.5 % to 21.9 %(P